Search

Your search keyword '"Hardisson D"' showing total 329 results

Search Constraints

Start Over You searched for: Author "Hardisson D" Remove constraint Author: "Hardisson D"
329 results on '"Hardisson D"'

Search Results

2. Common non-synonymous SNPs associated with breast cancer susceptibility: Findings from the Breast Cancer Association Consortium

3. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.

8. One-step nucleic acid amplification (OSNA) of Sentinel Lymph Node in Early Stage Endometrial Cancer: Spanish Multicenter Study (ENDO-OSNA).

9. Detection of lymph node metastases using pooling method by One-Step Nucleic Acid Amplification (OSNA) assay in prostate cancer patients: Preliminary results

12. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group For Ovarian Cancer Research (GEICO)

15. 860P Redefining prognosis in early-stage high-grade endometrial cancer

16. 862P Prognostic role of CD3, CD4, CD8 and FOXP3 positive populations in early-stage endometrial carcinoma

17. 32P Comparison of fully automated microsatellite instability test to immunohistochemistry for mismatch repair protein expression in endometrial carcinoma

22. Versatile Electroanalytical Bioplatforms for Simultaneous Determination of Cancer-Related DNA 5-Methyl- and 5-Hydroxymethyl-Cytosines at Global and Gene-Specific Levels in Human Serum and Tissues

28. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?

33. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

34. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

35. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

36. Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

37. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

38. Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

39. Micro-RNA profile in advanced metastatic breast cancer as a predictive tool for response to bevacizumab-paclitaxel

40. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

45. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

49. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

Catalog

Books, media, physical & digital resources